Fresenius Medcl Company Profile
What is the competitive landscape for FRESENIUS MEDCL
FRESENIUS MEDCL has nine approved drugs.
There are three US patents protecting FRESENIUS MEDCL drugs.
Summary for Fresenius Medcl
| US Patents: | 3 |
| Tradenames: | 22 |
| Ingredients: | 5 |
| NDAs: | 9 |
Drugs and US Patents for Fresenius Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Medcl Care | PHOSLYRA | calcium acetate | SOLUTION;ORAL | 022581-001 | Apr 18, 2011 | DISCN | Yes | No | 8,592,480 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fresenius Medcl | INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER | calcium chloride; dextrose; sodium chloride; sodium lactate | SOLUTION;INTRAPERITONEAL | 019395-001 | Mar 26, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Fresenius Medcl | DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER | calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate | SOLUTION;INTRAPERITONEAL | 020171-002 | Aug 19, 1992 | AT | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Medcl Care | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | 4,870,105 | ⤷ Start Trial |
| Fresenius Medcl Care | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | 4,870,105 | ⤷ Start Trial |
| Fresenius Medcl Care | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 4,870,105 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 667 mg/5 mL | ➤ Subscribe | 2013-12-05 |
| ➤ Subscribe | Capsules | EQ 169 mg calcium | ➤ Subscribe | 2005-05-31 |
International Patents for Fresenius Medcl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2009104774 | ⤷ Start Trial |
| South Korea | 101553719 | ⤷ Start Trial |
| European Patent Office | 2048948 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Medcl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340828 | LUC00195 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
| 2203431 | CR 2015 00014 | Denmark | ⤷ Start Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 2957286 | 6/2019 | Austria | ⤷ Start Trial | PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
